Neurology Today

Skip Navigation LinksHome > Collections > Multiple Sclerosis

Multiple Sclerosis

Created:   1/26/2010
Contains:  95 items

Show
Previous of 1 Next

News from the Congress of ECTRIMS: Siponimod Found to Slow Disability Progression in Advanced MS

Free Access
PDF
+ Favorites
Request Permissions

News from the Congress of ECTRIMS: New Imaging Tracers Shed Light on Microglial Activation in MS

Free Access
PDF
+ Favorites
Request Permissions

News from the Congress of ECTRIMS: Neurofilament Blood Test Could Potentially Help Monitor MS Progression, Study Finds

Free Access
PDF
+ Favorites
Request Permissions

News from the Congress of ECTRIMS: Novel Imaging Tracers Detect Microglial Activation in White Matter Lesions in MS Patients

Free Access
PDF
+ Favorites
Request Permissions

Bringing the Patient-Centered Specialty Practice Model to Multiple Sclerosis Patients

Free Access
PDF
+ Favorites
Request Permissions

Five Steps for Cost Cutting in MS Treatment

Free Access
PDF
+ Favorites
Request Permissions

Long-Term Study Supports Benefits of Treating MS at First Possible Signs

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Retinal Thickness Predicts MS Worsening Two to Five Years Out, Offering Useful Clinical and Trial Markers, Study Finds

Free Access
PDF
+ Favorites
Request Permissions

Comorbidities in MS Found to Increase Psychological Problems

Free Access
PDF
+ Favorites
Request Permissions

News from the ECTRIMS Congress: Two New Studies on Natalizumab: Is Extending the Time Between Doses Safe? Can Dosing Be Stopped During Pregnancy?

Free Access
PDF
+ Favorites
Request Permissions

News from the ECTRIMS Annual Meeting: Ocrelizumab Reported to be Effective Against MS in Three Trials

Free Access
PDF
+ Favorites
Request Permissions

IN THE CLINIC: Daniel S. Reich, MD, PhD: On His Work at the NIH, Developing New Imaging Techniques in Human and Animal Models of MS

Free Access
PDF
+ Favorites
Request Permissions

Third PML Case Associated with Fingolimod: How to Distinguish PML from MS Relapse

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE CONSORTIUM OF MS CENTERS ANNUAL MEETING: Fingolimod Found Effective in Nearly All Subgroups Up to Three Years Post-Diagnosis

Free Access
PDF
+ Favorites
Request Permissions

A New Genetic Study Associates Low Vitamin D and Risk for Multiple Sclerosis

Free Access
PDF
+ Favorites
Request Permissions

New Study Suggests Brain Is Connected to the Lymphatic System: What the Discovery Could Mean for Neurology

Free Access
PDF
+ Favorites
Request Permissions

News from the Consortium of MS Centers Annual Meeting: Post Hoc Analysis: Benefits of Interferon Beta-1A Found in Patients with More Advanced MS

Free Access
PDF
+ Favorites
Request Permissions

News from the Consortium of MS Centers Annual Meeting: Lymphopenia Associated with Dimethyl Fumarate Disproportionately Lowers CD8+ Cells in MS

Free Access
PDF
+ Favorites
Request Permissions

News from the Consortium of MS Centers Annual Meeting: BMI Linked to Risk of MS Progression in Observational Study

Free Access
PDF
+ Favorites
Request Permissions

News from the Consortium of MS Centers Annual Meeting: Patient-Centered Functional Outcomes Improve More on Daclizumab than on Interferon Beta-1A: New Data from DECIDE

Free Access
PDF
+ Favorites
Request Permissions

Netrin 1 Regulates the Permeability of the Blood-Brain Barrier, Offering Potential Neuroprotection Against MS

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Studies Find No Effect of Fat, Fiber, or Salt Intake on Risk of MS, But Hints of Micronutrients

Free Access
PDF
+ Favorites
Request Permissions

Two Topical Drugs Found to Promote Functional Remyelination in Cellular Models of Multiple Sclerosis

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: Multiple Sclerosis: Spontaneous Remyelination, Visualized With PET Tracer, Could Be Marker of Clinical Course

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: High-Dose Vitamin D Improved Immune Markers for Relapsing-Remitting MS

Free Access
PDF
+ Favorites
Request Permissions

Dr. Bhupendra Khatri: A New Look at Why Doctors Should Be ‘Healing the Soul’

Free Access
PDF
+ Favorites
Request Permissions

The AAN Weighs In On ‘Step Edits’ for MS Drugs

Free Access
PDF
+ Favorites
Request Permissions

INSIDE THE AAN SECTIONS: The Multiple Sclerosis Section — Navigating Escalating Costs and New Treatment Frontiers

Free Access
PDF
+ Favorites
Request Permissions

LEGAL-EASE: Supreme Court Ruling on Patent Case Gives Teva Pharmaceuticals More Time to Market Copaxone for MS Without Generic Drug Competition

Free Access
PDF
+ Favorites
Request Permissions

Stem Cell Transplant Results in MS Build Support for Large Randomized Trials

Free Access
PDF
+ Favorites
Request Permissions

VIDEOS ON DEMAND: Multiple sclerosis: What is the evidence for the benefits of a low-sodium diet?

Free Access
PDF
+ Favorites
Request Permissions

Best Advances of 2014: Picks from the Neurology Today Editorial Advisory Board

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE JOINT MEETING OF ACTRIMS/ECTRIMS: No Evident Disease Activity — How It Appears in Clinical Trials and Clinical Practice

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE JOINT MEETING OF ACTRIMS/ECTRIMS: Stem Cell Therapy in MS Looks Safe; Test of Efficacy Awaits Future Trials

Free Access
PDF
+ Favorites
Request Permissions

Early Trial of Experimental Antisense Drug Shows Promising Reduction in New Lesions in Relapsing-Remitting Multiple Sclerosis

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE JOINT MEETING OF ACTRIMS/ECTRIMS: Clinical Trial Moves Generic Glatiramer Acetate Closer to the Clinic New Benefits, Challenges in the Era of Generics in Neurology

Free Access
PDF
+ Favorites
Request Permissions

MONTHLY DACLIZUMAB FOUND SUPERIOR TO INTERFERON BETA-1A FOR RELAPSING-REMITTING MS

Free Access
PDF
+ Favorites
Request Permissions

Human Study Links High Dietary Sodium to Increase in MS Exacerbations

Free Access
PDF
+ Favorites
Request Permissions

Myelinating Oligodendrocytes Derived from Primary Progressive MS Patients: Scientists Developed Faster, More Efficient Methodology

Free Access
PDF
+ Favorites
Request Permissions

VIDEOS ON DEMAND: Can vitamin D suppress multiple sclerosis?

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: Synthetic Version of Vitamin D Helps with MS Fatigue, New Study Suggests

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: RXR Agonist Shows Potential for Myelin Repair In Vitro, New Study Suggests

Free Access
PDF
+ Favorites
Request Permissions

High-Dose Oral Steroids Found to Be As Effective As IV Steroids for MS Relapses

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: Thalamic Atrophy Seen in Cases of Radiologically Isolated Syndrome — A Predictor of MS Progression

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: Pregnancy Hormone Found to Reduce Relapses in Women with MS

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: A Potential New Diagnostic Tool to Help Distinguish MS from Transient Illness in Children

Free Access
PDF
+ Favorites
Request Permissions

Functional Brain Abnormalities Linked to Cognitive Impairments in MS Patients Who Use Marijuana

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: New Insight on the Role of the Gut Microbiome in Multiple Sclerosis

Free Access
PDF
+ Favorites
Request Permissions

New Supreme Court Case & the Complicated Accounting of MS Drugs

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: PET Imaging Enables Better Differentiation of Lesions in Secondary Progressive MS

Free Access
PDF
+ Favorites
Request Permissions

A Statin Is Found to Ameliorate Late-Stage Disability in MS: Experts Call for Phase 3 Trial

Free Access
PDF
+ Favorites
Request Permissions

FROM THE AAN: A New Evidence-Based Guideline on Complementary and Alternative Medicine for MS

Free Access
PDF
+ Favorites
Request Permissions

Will New Data on Gray Matter Dysfunction in MS Upend Theory on Disease Demyelination?

Free Access
PDF
+ Favorites
Request Permissions

PML in Suspected MS Patient Taking Fingolimod Raises FDA Concerns

Free Access
PDF
+ Favorites
Request Permissions

Glaxo Under Fire Over MS Clinical Trial Allegations at R&D Center in China

Free Access
PDF
+ Favorites
Request Permissions

PML Reported in Patients Taking Psoriasis Compounds Sharing Ingredient with Oral MS Drug

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: What Are the Risks That Radiologically Isolated Syndrome Will Convert to MS?

Free Access
PDF
+ Favorites
Request Permissions

With New Oral Ms Drug, New Therapeutic Options

Free Access
PDF
+ Favorites
Request Permissions

Cognitive Impairment May Vary Depending on the Type of MS

Free Access
PDF
+ Favorites
Request Permissions

Imaging Tracks Fibrinogen Activity in MS Brain Inflammation

Free Access
PDF
+ Favorites
Request Permissions

Amyloid Beta Reverses MS-like Disease in Mice. Is It Time to Re-evaluate Amyloid Elsewhere?

Free Access
PDF
+ Favorites
Request Permissions

Serum Levels of Antibodies to a Potassium Channel Found Higher in People with MS

Free Access
PDF
+ Favorites
Request Permissions

Interferon Found Not to Slow MS Disability Progression

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: For MS Patients, No Additive Benefit Found in Combining Glatiramer Acetate and Interferon Beta-1A

Free Access
PDF
+ Favorites
Request Permissions

Levels of Risk Identified for MS Patients Taking Natalizumab

Free Access
PDF
+ Favorites
Request Permissions

Fatty Acids Quell Myelin Inflammation in MS model

Free Access
PDF
+ Favorites
Request Permissions

Citing Possible Heart Risks, FDA Recommends Increased Monitoring, Tighter Indications, for MS Patients Prescribed Fingolimod

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Novel Agent Reduces MS. Lesions in Early Trial

Free Access
PDF
+ Favorites
Request Permissions

Will Firategrast, Another Monoclonal Antibody Therapy for MS, Prove a Safe, Effective Alternative?

Free Access
PDF
+ Favorites
Request Permissions

Young Immune Systems Can Rejuvenate Remyelinating Ability

Free Access
PDF
+ Favorites
Request Permissions

A Game-Changer in MS Pathogenesis: New Evidence for Early Cortical Inflammation as Primary Target for Therapy

Free Access
PDF
+ Favorites
Request Permissions

Ocrelizumab Succeeds in Phase 2 Trial, Broadening the MS Treatment Landscape

Free Access
PDF
+ Favorites
Request Permissions

News from ECTRIMS/ACTRIMS Fifth Triennial Conference: MS Drugs Take Center Stage at ECTRIMS/ACTRIM: Weighing their Pros and Cons

Free Access
PDF
+ Favorites
Request Permissions

News from the ANA Annual Meeting: MS Death Rate Lower with Early Interferon Use, Study Shows

Free Access
PDF
+ Favorites
Request Permissions

A New Oral Drug for MS: How Does it Compare?

Free Access
PDF
+ Favorites
Request Permissions

MS Experts Highlight Favorite Papers on MS — From Predicting the Course of Disease to Comparing New to Standard Therapies

Free Access
PDF
+ Favorites
Request Permissions

Lessons Learned from Post‐Marketing Experience with PML‐Associated Natalizumab

Free Access
PDF
+ Favorites
Request Permissions

MS Specialists Question Company Disclosure of Natalizumab‐Associated PML

Free Access
PDF
+ Favorites
Request Permissions

New Cases Present an Evolving Picture of Progressive Multifocal Leukoencephalopathy

Free Access
PDF
+ Favorites
Request Permissions

Changing Therapy After Breakthrough MS Improves Relapse Rate

Free Access
PDF
+ Favorites
Request Permissions

New Safety Data Reported on Natalizumab for MS and PML Risk

Free Access
PDF
+ Favorites
Request Permissions

MS ANTISENSE DRUG SHOWS EARLY PROMISE, BUT LONG‐TERM BENEFIT REMAINS UNKNOWN

Free Access
PDF
+ Favorites
Request Permissions

New Approaches to Dealing with PML, Meningitis, and Encephalitis

Free Access
PDF
+ Favorites
Request Permissions

Autopsy Reveals New Effects of Natalizumab on CNS Immune System

Free Access
PDF
+ Favorites
Request Permissions

Neurologists Turn to FDA MedWatch to Stay Informed on Drug Safety

Free Access
PDF
+ Favorites
Request Permissions

Two More Patients on Natalizumab Develop PML

Free Access
PDF
+ Favorites
Request Permissions

Reports of PML in Transplant Patients Prompt FDA Review

Free Access
PDF
+ Favorites
Request Permissions

Interferon Nab Testing for MS: Case Studies

Free Access
PDF
+ Favorites
Request Permissions

FAMILIAR T‐CELL SUPPRESSION SEEN IN MS PATIENTS TAKING NATALIZUMAB

Free Access
+ Favorites
Request Permissions

NEW STUDIES SHOW NATALIZUMAB BENEFITS MS PATIENTS

Free Access
+ Favorites
Request Permissions

FDA PANELISTS OFFER INSIDE TRACK TO DECISION ON NATALIZUMAB

Free Access
+ Favorites
Request Permissions

DESPITE COMPLICATIONS, ‘PRELIMINARY STEPS’ UNDERWAY TO RESTART NATALIZUMAB TRIALS

Free Access
+ Favorites
Request Permissions

NATALIZUMAB DEBACLE RAISES QUESTIONS ABOUT FAST‐TRACK PROGRAM

Free Access
+ Favorites
Request Permissions

Dr. Philip L. De Jager: Two Distinct RNA Profiles for MS Patients Show Different Disease Activity

Creator: Jamie Talan
Duration: 9:15
Neurology Today October 18, 2012, Volume 12, Issue 20;
Philip L. De Jager, MD, PhD, associate professor of neurology at Harvard University, describes the investigation that unraveled two distinct RNA profiles for MS patients, reflecting different levels of disease activity.

Download (8.48 MB)
+ Favorites

Investigational Novel Agent Reduces MS Lesions

Neurology Today

ONO-4641, an investigational oral drug, reduced the number of lesions detected by MRI in people with relapsing remitting multiple sclerosis (RRMS) — the primary outcome for the phase 2b Drug Research EvaluAtion for MS (DreaMS) trial. Here, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the growing interest in these oral and increasingly expensive MS drugs.
For the full-text article, see the June 7 issue of Neurology Today.

Play Video
+ Favorites
Show
Previous of 1 Next
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.